CRP and coronary artery disorder: Concordantly, the Cardiovascular Inflammation Reduction Trial in 4786 patients with previous myocardial infarction or multivessel coronary disease showed no reduction in IL1β, IL6 or CRP levels and correspondingly did not show any reduction in cardiovascular events among patients treated with methotrexate compared to placebo42.